Nutraceutical giant TCI Co. and its medical device subsidiary Maxigen Biotech both reported positive January results, with expectations for double-digit growth throughout 2026.

• TCI Co.: Reported January revenue of NT$600 million (+12.2% YoY). Chairman Vincent Lin noted that the profit structure has stabilized after a period of business optimization in 2025. TCI has successfully secured over ten global clients with annual revenues exceeding US$1 billion. New production lines in the U.S. are now operational, and the company is breaking through in the Japanese and European markets.
• Maxigen Biotech: Reported NT$72.96 million (+7.9% YoY). Formerly a manufacturer, Maxigen is successfully transitioning into a global medical device brand. While maintaining its stronghold in the U.S. and Europe, it is seeing steady development in emerging markets across Africa, Latin America, and the Middle East.

Resource: 大江元月營收年增12% 和康生+7.9%